Partner Contact

Our ref

John Williamson-Noble Chris Morse T +61 2 9263 4778 cmorse@gtlaw.com.au JWN:CJM:1049593



L 35, Tower Two, International Towers Sydney 200 Barangaroo Avenue, Barangaroo NSW 2000 AUS T +61 2 9263 4000 F +61 2 9263 4111 www.gtlaw.com.au

20 March 2023

#### **Online lodgement**

Market Announcements Office ASX Limited Exchange Centre 20 Bridge Street Sydney NSW 2000

Dear Sir / Madam

## Takeover bid by Australian Clinical Labs Limited for Healius Limited - notice of people to whom information is to be sent

We act for Australian Clinical Labs Limited (ABN 94 645 711 128) (ASX:ACL) (ACL).

We attach, by way of service pursuant to subsection 633(4)(a) of the *Corporations Act 2001* (Cth) (**Corporations Act**), a notice confirming the people to whom information is to be sent under items 6 and 12 of subsection 633(1) of the Corporations Act in relation to ACL's proposed off-market takeover bid under Chapter 6 of the Corporations Act for all the fully paid ordinary shares in Healius Limited (ABN 24 064 530 516) (ASX:HLS).

Yours faithfully Gilbert + Tobin

John Williamson-Noble Partner +61 2 9263 4030 jwilliamson-noble@gtlaw.com.au

-		
A	×	
K		
$\bigcirc$		

Chris Morse Partner +61 2 9263 4778 cmorse@gtlaw.com.au

#### AUSTRALIAN CLINICAL LABS LIMITED (ABN 94 645 711 128)

### COMPANY NOTICE - SUBSECTION 633(2) OF THE CORPORATIONS ACT 2001 (CTH)

# Notice of people to whom information is to be sent under items 6 and 12 of subsection 633(1) of the *Corporations Act 2001* (Cth)

To: Healius Limited (ABN 24 064 530 516) (ASX: HLS)

In accordance with subsection 633(2) of the *Corporations Act 2001* (Cth) (**Corporations Act**), Australian Clinical Labs Limited (ABN 94 645 711 128) (**ACL**) has set 7.00pm (Sydney time) on 21 March 2023 as the time and date for determining the people to whom information is to be sent under items 6 and 12 of subsection 633(1) of the Corporations Act in relation to its off-market takeover bid for all of the ordinary shares in Healius Limited (ABN 24 064 530 516) as described in ACL's bidder's statement dated 20 March 2023.

Date: 20 March 2023

Signed for and on behalf of Australian Clinical Labs Limited by:

Bleans Padue

Eleanor Padman Company Secretary